Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility - Theratechnologies (NASDAQ:THTX)
- Removal of Minimum Liquidity Covenant of US$30 Million if F8 Formulation of Tesamorelin is Not Approved by the FDA by March 31, 2024 - Minimum Liquidity Covenant to Decrease Over Time to a Minimum of US$15 million
United States Julie Schneiderman Philippe Dubuc Toronto Stock Exchange Theratechnologies Inc Communications Corporate Affairs
Source: benzinga.com